Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Alzheimer's Disease: Update Bulletin #3 [August 2018]

Product Code:
Publication Date:
August 2018

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the Alzheimer's disease (AD) market. KOLs gave their candid insights on the following events: Eisai and Biogen announcing detailed results from a Phase II study (Study 201) with BAN2401; AC Immune/Genentech announcing completion of recruitment for its second Phase III (CREAD 2) study of crenezumab; and Biohaven announcing that it had initiated a Phase II/III clinical trial of trigriluzole (BHV-4157), a novel glutamate modulator, in patients with mild-to-moderate AD.

Business Questions:

• How do KOLs view the latest Phase II data for Eisai and Biogen’s BAN2401?
• What criticisms do KOLs have on the design of Study 201 and how will it impact Phase III testing?
• Do KOLs have any safety concerns with BAN2401?
• According to KOLs, what advantages can Eisai/Biogen carry into Phase III testing for BAN2401?
• What do KOLs think of a high dosage biweekly dosing regimen for BAN2401?
• What do experts think of CSF biomarkers and the tau protein in terms of the development of AD therapies?
• Are KOLs excited by the prospects of AC Immune/Genentech’s crenezumab in AD patients with mild cognitive impairment?
• Will a less frequent dosing schedule of crenezumab provide any advantage?
• Will crenezumab deliver positive outcomes in Phase III trials?
• How do KOLs view Biohaven’s next generation glutamate modulator trigriluzole?
• What safety concerns do KOLs have with glutamate modulators?
• What advice do KOLs have for Biohaven for the Phase III development of trigriluzole?


All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved